BR112022021957A2 - Imidazopirimidinas como moduladores de il -17 - Google Patents

Imidazopirimidinas como moduladores de il -17

Info

Publication number
BR112022021957A2
BR112022021957A2 BR112022021957A BR112022021957A BR112022021957A2 BR 112022021957 A2 BR112022021957 A2 BR 112022021957A2 BR 112022021957 A BR112022021957 A BR 112022021957A BR 112022021957 A BR112022021957 A BR 112022021957A BR 112022021957 A2 BR112022021957 A2 BR 112022021957A2
Authority
BR
Brazil
Prior art keywords
imidazopyrimidines
modulators
ameliorate
syndrome
treat
Prior art date
Application number
BR112022021957A
Other languages
English (en)
Portuguese (pt)
Inventor
Xue Xiaohua
Goldberg Steven
Martin Connor
B Rhorer Timothy
M Tanis Virginia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112022021957A2 publication Critical patent/BR112022021957A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fats And Perfumes (AREA)
BR112022021957A 2020-04-30 2021-04-28 Imidazopirimidinas como moduladores de il -17 BR112022021957A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017679P 2020-04-30 2020-04-30
PCT/IB2021/053517 WO2021220183A1 (en) 2020-04-30 2021-04-28 Imidazopyrimidines as modulators of il-17

Publications (1)

Publication Number Publication Date
BR112022021957A2 true BR112022021957A2 (pt) 2023-01-17

Family

ID=75769661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021957A BR112022021957A2 (pt) 2020-04-30 2021-04-28 Imidazopirimidinas como moduladores de il -17

Country Status (12)

Country Link
US (1) US12559496B2 (cg-RX-API-DMAC10.html)
EP (1) EP4143193B1 (cg-RX-API-DMAC10.html)
JP (1) JP7661361B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230018387A (cg-RX-API-DMAC10.html)
CN (1) CN115867348B (cg-RX-API-DMAC10.html)
AU (1) AU2021262588A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022021957A2 (cg-RX-API-DMAC10.html)
CA (1) CA3181793A1 (cg-RX-API-DMAC10.html)
ES (1) ES3071556T3 (cg-RX-API-DMAC10.html)
IL (1) IL297734A (cg-RX-API-DMAC10.html)
MX (1) MX2022013650A (cg-RX-API-DMAC10.html)
WO (1) WO2021220183A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
EP4486737A1 (en) 2022-03-04 2025-01-08 LEO Pharma A/S Small molecule modulators of il-17
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
EP4688156A1 (en) * 2023-03-28 2026-02-11 Janssen Pharmaceutica NV Lactam-containing imidazopyridazine il-17 inhibitor compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809660B1 (en) * 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
MA40759A (fr) * 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
US10152431B2 (en) 2015-03-16 2018-12-11 Honeywell International Inc. System and method for remote set-up and adjustment of peripherals
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN111601799B (zh) 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
WO2020011731A1 (en) 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
JP7664947B2 (ja) 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
KR20230017211A (ko) 2020-04-30 2023-02-03 얀센 파마슈티카 엔.브이. Il-17 경로의 조절인자를 식별하는 방법
WO2021219784A1 (en) 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv New triazinoindole compounds

Also Published As

Publication number Publication date
CN115867348B (zh) 2025-05-06
AU2021262588A1 (en) 2023-01-19
CA3181793A1 (en) 2021-11-04
ES3071556T3 (en) 2026-06-24
JP2023523770A (ja) 2023-06-07
EP4143193C0 (en) 2026-04-22
CN115867348A (zh) 2023-03-28
WO2021220183A1 (en) 2021-11-04
US20230242537A1 (en) 2023-08-03
MX2022013650A (es) 2023-02-01
US12559496B2 (en) 2026-02-24
EP4143193B1 (en) 2026-04-22
JP7661361B2 (ja) 2025-04-14
IL297734A (en) 2022-12-01
KR20230018387A (ko) 2023-02-07
EP4143193A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
BR112022021962A2 (pt) Imidazopiridazinas como moduladores de il-17
EA202191630A1 (ru) ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ
JOP20220130B1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
JOP20230124A1 (ar) تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
BR112022000231A2 (pt) Novos métodos
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
CY1122565T1 (el) Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
CY1121851T1 (el) Προφαρμακα toy alvocidib που εχουν αυξημενη βιοδιαθεσιμοτητα
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
BR112017026057A2 (pt) profármacos constituídos por um conjugado linker de ácido hialurônico e agonista duplo de glp-1/glucagon
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112014003704A2 (pt) moduladores ror gama
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
DOP2024000051A (es) Compuestos de imidazopiridazina inhibidores de il-17
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements